Institutional members access full text with Ovid®

Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies

Canducci, Filippoa; Sampaolo, Michelaa; Marinozzi, Maria Chiaraa; Boeri, Enzob; Spagnuolo, Vincenzoc; Galli, Andreac; Castagna, Antonellac; Lazzarin, Adrianoa,c; Clementi, Massimoa,b; Gianotti, Nicolac

doi: 10.1097/QAD.0b013e328323da60
Basic Science: Concise Communication

Objective: Evaluate HIV-1 subtype B integrase gene evolution in patients failing raltegravir (RAL)-based savage regimens by clonal analysis of the replicating viral quasispecies.

Design: Seven triple class failure HIV-1 (subtype B)-infected patients, followed at San Raffaele Hospital and enrolled in the RAL Expanded Access Program (MK0518-023), were evaluated. Patients were followed up for 24–48 weeks and due to the absence of other active drugs, RAL was maintained in their regimens even if resistance mutations were detected.

Methods: Immunologic and virologic parameters were recorded every 4 weeks, and amplification and clonal analysis of viral populations were performed at baseline and every 4–12 weeks in all patients.

Results: Resistance to RAL appeared initially associated with selection of single variants (Y143R, Q148R N155H) in the majority of patients; however, in three patients, complex patterns of viral mutations were observed. The clonal analysis of viral quasispecies allowed to describe the evolution of each viral population and the progressive accumulation of RAL resistance-associated mutations and polymorphisms associated with therapy failure.

Conclusion: The complex patterns of resistance mutations observed, including novel variants evolved under continuous RAL pressure, suggesting that they are the result of the equilibrium between drug resistance and enzyme function. Despite the efficacy of this compound, our data discourage its use in a functional monotherapy and maintaining RAL even in presence of RAL resistance-associated mutations may lead to the progressive formation of viral reservoirs with multiple integrase inhibitor-resistant variants that may limit the future efficacy of other integrase inhibitors due to cross-resistance.

aUniversità Vita-Salute San Raffaele, Italy

bDiagnostica e Ricerca San Raffaele, Italy

cDivisione di Malattie Infettive, Istituto Scientifico San Raffaele, Milan, Italy.

Received 19 September, 2008

Revised 14 November, 2008

Accepted 22 November, 2008

Correspondence to Filippo Canducci, MD, PhD, Università Vita-Salute San Raffaele, Via Olgettina 58, Milan, Italy. Tel: +390226434284; e-mail: canducci.filippo@hsr.it

© 2009 Lippincott Williams & Wilkins, Inc.